US20030072717A1 - Inhalation device having an optimized air flow path - Google Patents
Inhalation device having an optimized air flow path Download PDFInfo
- Publication number
- US20030072717A1 US20030072717A1 US10/080,504 US8050402A US2003072717A1 US 20030072717 A1 US20030072717 A1 US 20030072717A1 US 8050402 A US8050402 A US 8050402A US 2003072717 A1 US2003072717 A1 US 2003072717A1
- Authority
- US
- United States
- Prior art keywords
- compound
- outlet
- reservoir
- particles
- ejection head
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/02—Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/02—Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
- A61M15/025—Bubble jet droplet ejection devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/007—Syringe-type or piston-type sprayers or atomisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0085—Inhalators using ultrasonics
Definitions
- the present invention generally relates to a device for the pulmonary delivery of an aerosolized compound.
- the device is particularly suitable for the pulmonary delivery of a pharmaceutical compound but may be used for other purposes.
- MDI metered dose inhaler
- DPI dry powder inhaler
- Nebulizers deliver the pharmaceutical through generating an aerosol by atomizing a liquid.
- An embodiment of this invention provides devices for delivery of an aerosolized compound, such as a pharmaceutical compound, to a patient via the pulmonary route, using an electronic ejection device.
- An embodiment of this invention comprises air paths specifically designed to minimize turbulence.
- an embodiment of the present invention provides less deposition of aerosolized compound within the inhaler and a more effective transfer of the dispensed material into the inhaled air stream.
- One embodiment of the present invention relates to a device that comprises a reservoir for storing a compound, wherein a reservoir is fluidly connected to a system for generating liquid particles of a desired size (or size range) containing a compound.
- This system comprises an entry port and an element to generate particles of the desired size for ejection from an ejection head of the element.
- At least the ejection head of the particle-generating element is disposed within a housing designed to generate a substantially unobstructed airflow path, substantially non-turbulent airflow, or substantially laminar airflow for delivery of the compound.
- the housing comprises an inlet and an outlet, and provides for substantially unobstructed airflow between the ejection head and the outlet when air traverses the airflow path from inlet to outlet.
- the ejection head is disposed in the airflow path downstream of the inlet and upstream from the outlet.
- Another embodiment of the invention relates to a method for delivering an aerosolized compound to a patient using a device according to the invention.
- Such a method comprises inhaling air through such a device while the particle-generating system of the device is actuated.
- Use of the term “while” encompasses during, immediately thereafter, immediately before, or any such moment that is temporally closely related.
- Another embodiment of the invention relates to a method for generating an air stream containing a compound. This method comprises drawing air through a device of the invention from inlet to outlet while actuating the particle-generating system of the device.
- FIG. 1 illustrates one embodiment of the device according to the invention.
- FIG. 2 illustrates a system to generate particles of the desired size according to an embodiment of the invention.
- the reservoir and particle-generating system of a device may be disposed within, partially within, or outside of the housing of the device.
- the reservoir, if included, within the housing, may be aerodynamically shaped.
- the reservoir is detachable and/or replaceable.
- the reservoir and particle-generating system are integrated into a single detachable and/or replaceable unit.
- the system for generating particles can be any system that generates particles of the desired size or size range.
- this system is a digitally controlled electronic droplet ejection device.
- Other embodiments of digitally controlled electronic droplet ejection devices useful in the practice of the invention include those that use heat or a piezoelectric component to generate particles that are ejected from the ejection head.
- the size of the particles is a size that allows the particles to transit to and be deposited in the alveoli. This size may be where at least about 90% of the particles range in size from about 1 ⁇ m to about 5 ⁇ m such as where the particles have a mass median aerodynamic diameter of about 3 ⁇ m. For example, at least about 60% of the particles may have a mass median aerodynamic diameter of about 3 ⁇ tm.
- the housing may be of any size, shape and matter that allows for substantially unobstructed airflow.
- the airflow may be substantially laminar prior to exiting the housing outlet.
- the housing's inner surface proximal to the ejection head and extending to the outlet may be contoured to minimize turbulence.
- This substantially unobstructed airflow may comprise a substantially homogeneous mixture of the ejected compound and air in the airflow prior to exiting the housing outlet.
- the term “reservoir” shall be interpreted to mean any container which is suitable to hold and store a compound.
- the reservoir may be of any shape, size, or material and may be aerodynamically designed so as to facilitate airflow and decrease obstructions in the airflow path.
- the relative size and optimal shape of the reservoir with respect to other components is variable. For example, altering the size and/or shape of the reservoir may have an impact on the aerodynamics of the system.
- the reservoir may have an outer layer of material which may be aerodynamically designed, and an inner collapsible bag which is suitable to hold and store a compound.
- the reservoir is filled with a compound to be administered and may be sealed or have a vent hole through the outer material to allow air displacement for the inner collapsible bag.
- the reservoir is fluidly connected to the system and may be either permanently connected or may be detachably connected so as to refill the reservoir with a compound.
- system or “particle-generating system” shall be interpreted to mean any device that can act as an ejection means to eject particles into the airflow.
- the system may compromise a piezoelectric device, such as the kinds (thermal and piezo) used in ink jet printing.
- particles shall be interpreted to mean small droplets of the compound which are formed upon ejection from the ejection head of the element.
- the term “desired size” shall be interpreted to mean a size which is sufficiently small such that when the particles are formed, they remain suspended in the air for a sufficient amount of time such that they may be inhaled and are sufficiently small such that the particles may be deposited in alveoli upon reaching the lungs.
- the particles may range in size from about 1 ⁇ m to about 5 ⁇ m in diameter, such as a mass median aerodynamic diameter of about 3 ⁇ m.
- a compound stored in the reservoir of the system can be in any form, and is preferably a liquid formulation.
- the compound may be any pharmaceutical compound, for example, a protein, a small molecule, or a gene delivery vehicle.
- Preferred protein embodiments include EPO, G-CSF, GM-CSF, insulin, hGH, factor VIII, FSH, LH, VEGF, an interferon, an interleukin, an antibody or antibody fragment (alone or conjugated to another compound, for example, a cytotoxic agent).
- Small molecule embodiments include nicotine, methotrexate, albuterol, methadone, or cromylin.
- Still other embodiments of pharmaceutical compounds include a gene delivery vehicle such as a virus, a liposome, a nucleic acid, a nucleic acid complex, or suspensions thereof.
- compound shall be interpreted to mean any fluid or liquid formulation such as any pharmaceutical compound.
- small molecule shall be interpreted to mean any molecule having fewer than one hundred (100) non hydrogen atoms, and having a molecular weight of less than about 1 kDalton.
- fluidly connected shall be interpreted to mean a connection whereby a fluid may be transferred from the reservoir to the system.
- This fluid connection may be accomplished in any known way.
- Non-exclusive examples of such a connection are gravity, a pump, a channel, or capillary feed.
- exit port shall be interpreted to mean the area or point at which the compound enters the system.
- element to generate particles shall be interpreted to mean any delivery engine which can generate particles of the desired size.
- ejection head shall be interpreted to mean the area or point on the system where the particles of the compound are ejected into the air stream.
- housing shall be interpreted to mean any casing or encased area in which air may flow.
- outlet shall be interpreted to mean the area or point at which air enters the housing.
- outlet shall be interpreted to mean the area or point at which air exits the housing.
- airflow path shall be interpreted to mean the path that the air follows from the inlet to the outlet of the housing.
- the term “disposed” shall be interpreted to mean that the ejection head is connected in any way to the housing such that the ejection head is downstream of the inlet and upstream of the outlet. This connection may be aerodynamically designed such as to decrease airflow obstructions and decrease turbulence in the airflow path.
- substantially unobstructed airflow shall be interpreted to mean where the airflow path is substantially free of obstructions such as to decrease turbulence. By way of non-exclusive example, this may be accomplished by way of an aerodynamic airflow path.
- the term “pharmaceutical compound” shall be interpreted to mean any molecule or combination of molecules which are capable of performing a pharmaceutical function, e.g., a drug or prodrug which is effective in helping to prevent or treat a disease or condition. “Effective in helping to prevent or treat a disease or condition” indicates that administration in a clinically appropriate manner results in a beneficial effect for at least a statistically significant fraction of patients, such as a improvement of symptoms, a cure, a reduction in disease load, reduction in tumor mass or cell numbers, extension of life, improvement in quality of life, or other effect generally recognized as positive by medical doctors familiar with treating the particular type of disease or condition.
- pharmaceutical compound includes but is not limited to any protein, small molecule or gene delivery system.
- Prodrugs include chemical derivatives of a biologically-active parent compound which, upon administration, will eventually liberate the active parent compound in vivo.
- Use of prodrugs allows the artisan to modify the onset and/or duration of action in vivo.
- the use of prodrugs can modify the transportation into, the distribution or solubility of a drug in the body.
- prodrugs may reduce the toxicity and/or otherwise overcome difficulties encountered when administering a parent pharmaceutical compound.
- compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- compositions for use in accordance with the present invention thus may be formulated in conventional ways using one or more physiologically acceptable carriers comprising excipients which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- physiologically acceptable carriers comprising excipients which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- examples include but are not limited to surface tension-controlling agents, humectants, and viscosity-controlling agents; proper formulation may be dependent upon the specific pharmaceutical compound.
- gene delivery vehicle shall be interpreted to mean any method of delivering an intact gene into an organism such as adenoviral particles or other viruses modified for gene delivery, naked DNA, degradable matrices, and/or such gene delivery systems as mentioned in Dan Luo and W. Mark Saltzman, Synthetic DNA Delivery Systems, Nature Biotechnology, January 2000, at 33-37, which is incorporated herein by reference in its entirety.
- the term “electronic ejection device” shall be interpreted to mean any device which uses electronics to produce and eject particles of the desired size.
- the electronic ejection device includes, but is not limited to, a thermal device or a piezoelectric device such as those described in U.S. Pat. No. 5,894,841, which is incorporated herein by reference in its entirety.
- a typical thermal device comprises a liquid containing chamber provided with a configured array of nozzles and thin film resistors.
- a resistor is typically located directly behind each nozzle, for a given nozzle configuration.
- Each nozzle supplies a droplet or droplets (sometimes satellite droplets are created) of liquid from the chamber if and when a short electrical pulse energizes the corresponding resistor.
- the resistors thus function as an electronic ejection device.
- liquid in contact with the resistor is vaporized and forms a bubble.
- the vapor bubble grows rapidly and imparts momentum to liquid adjacent to a bubble.
- piezoelectric component shall be interpreted to mean a device generating particles of the desired size by a pressure wave in the fluid produced by applying a voltage pulse to a piezoelectric ceramic which acts as an electronic ejection device. The fluid is ejected through a fine aperture.
- a piezoelectric device is commonly used in inkjet printing.
- alveoli shall be interpreted to mean components in the pulmonary region of the lung where gas exchange occurs between the air and the lungs and the circulatory system.
- substantially laminar shall be interpreted to mean a substantially streamline steady flow at a substantially constant velocity. Air and entrained droplet flow is said to be laminar if the substance moves smoothly in layers, one layer (lamina) sliding relative to another. Viscosity and turbulence effects come into play if layers of the flowing substance change their shape as they move, as caused, for example, by airflow path surface irregularities, discontinuities, or the like.
- substantially homogeneous mixture shall be interpreted to mean a mixture approaching uniform composition throughout.
- contour to minimize turbulence shall be interpreted to mean that the housing is designed such that turbulence is minimized and that airflow is approaching substantially constant or smooth laminar flow.
- the inner walls of the housing may be sloped and/or smooth, or may be aerodynamically designed.
- aerosolized compound shall be interpreted to mean a volume of air of which has suspended droplets comprising the compound within it.
- the volume could be greater than 2 ml and less than 5 liters.
- substantially non-turbulent airflow shall be interpreted to mean that the housing is designed so as to reduce and/or minimize turbulence.
- FIGS. 1 - 2 One embodiment of the device is presented in FIGS. 1 - 2 .
- the device in FIG. 1 comprises a reservoir 1 for storing the compound to be delivered to the patient, a system 2 to generate particles of a desired size and a housing 7 .
- the system FIG. 2 comprises an entry port 4 and an element 5 to general particles of the desired size for ejection from an ejection head 6 of the element.
- the housing comprises an inlet 8 and an outlet 9 .
- the reservoir 1 in this embodiment is disposed within and extends along the length of the housing 7 and is fluidly connected to the system 2 at the entry port 4 and is connected to the housing at the inlet 8 by connection to a power source 10 such as a battery.
- the reservoir 1 pictured is a collapsible bladder, however, other forms of a reservoir may be used.
- the reservoir could be a cylinder fitted with a piston.
- the reservoir 1 in one embodiment, is sealed.
- the reservoir 1 may also be disposable and/or replaceable.
- system 2 is disposed entirely or partially within and extends along the length of the housing 7 and is disposed in the airflow path downstream of the inlet 8 and upstream from the outlet 9 .
- the system 2 may also be connected to the housing by suspension-like attachments 11 so as to keep the airflow substantially unobstructed.
- the ejection head 6 of the system 2 is disposed in the airflow path upstream of the outlet so as to provide for a mixture area in which the compound, after ejection from the ejection head, mixes with the air flowing from the inlet 8 to the outlet 9 for delivery to the patient.
- the element 5 to generate particles is of the kind used in a thermal ink jet printer.
- any device that will generate particles of the desired size may be used, such as those described in U.S. Pat. No. 5, 894 , 841 .
- the compound flows from the reservoir 1 into the element 5 through the entry port 4 and particles of the desired size are ejected from the ejection head 6 into the airflow path “A” which then delivers the compound to the patient.
- element 5 may comprise a silicon wafer, and may be as thick or thin as needed.
- a small particle size is preferred.
- particles ranging in size from about 1 ⁇ m to about 5 ⁇ m diameter are acceptable for the pulmonary delivery. Particles with a mass median aerodynamic diameter of about 3 ⁇ m are preferable.
- the particle size can be reduced by an optional heating element which can be employed to vaporize the liquid. Particle size can further be reduced by directing the particles ejected from the ejection head 6 at each another or at a suitable target to further fragment the particles.
- Housing 7 may provide for a substantially unobstructed airflow path so as to minimize turbulence so that the compound stored in the reservoir 1 may be efficiently delivered to the patient. Obstructions in the airflow path result in turbulence which results in some of the compound not reaching the patient. When there is turbulence, particles of the compound deposit on the side of the housing. Therefore, the physical shape and material of the components of the device may be altered so as to decrease turbulence.
- the reservoir, system and housing may be aerodynamically designed.
- the reservoir, system and housing may be constructed of materials that decrease turbulence.
- Suspension-like attachments 11 may be employed to secure the system to the housing to minimize obstructions and turbulence. Other forms of attachment may be used that minimize obstructions and turbulence.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 60/271,193 filed Feb. 23, 2001.
- The present invention generally relates to a device for the pulmonary delivery of an aerosolized compound. The device is particularly suitable for the pulmonary delivery of a pharmaceutical compound but may be used for other purposes.
- The following description of the background of the invention is provided to aid in understanding the invention, but is not admitted to be or to describe prior art to the invention.
- Recently there has been interest in developing devices and methods to systemically deliver pharmaceutical compositions, particularly those comprising a protein or peptide as the prophylactic or therapeutic agent, via or through the lungs of the patient. There are currently three primary device types for the delivery of pharmaceuticals to the respiratory tract.
- One such device type is the metered dose inhaler (“MDI”). MDIs use pressurized gas or propellant to deliver a burst of the compound or pharmaceutical into the patient's mouth during inhalation. A second type is the dry powder inhaler (“DPI”). DPIs use a burst of air to draw a dose of inactive powder into the bronchial tract. A third device type is a nebulizer. Nebulizers deliver the pharmaceutical through generating an aerosol by atomizing a liquid.
- These conventional device types, however, are not desirable for delivery of certain pharmaceuticals, particularly those intended for systemic administration to the patient. There are many reasons why these conventional devices are not desirable. For example, the precision of dose control and delivery of conventional devices such as MDIs, DPIs, and nebulizers is less accurate for pulmonary delivery, which is of particular concern where specific dosages or dosing regimens are required. Another reason is that pharmaceutical compositions often become attached to or stuck on the side of the device during delivery, thus decreasing the dosage. These devices are also dependent on user technique, which makes dosages variable from person to person and dose to dose.
- Thus there is a need to provide devices that are capable of efficient, effective, and consistent delivery of desired dosages of a systemic pharmaceutical to a patient via the pulmonary route.
- An embodiment of this invention provides devices for delivery of an aerosolized compound, such as a pharmaceutical compound, to a patient via the pulmonary route, using an electronic ejection device. An embodiment of this invention comprises air paths specifically designed to minimize turbulence.
- Advantageously, an embodiment of the present invention provides less deposition of aerosolized compound within the inhaler and a more effective transfer of the dispensed material into the inhaled air stream.
- One embodiment of the present invention relates to a device that comprises a reservoir for storing a compound, wherein a reservoir is fluidly connected to a system for generating liquid particles of a desired size (or size range) containing a compound. This system comprises an entry port and an element to generate particles of the desired size for ejection from an ejection head of the element. At least the ejection head of the particle-generating element is disposed within a housing designed to generate a substantially unobstructed airflow path, substantially non-turbulent airflow, or substantially laminar airflow for delivery of the compound. The housing comprises an inlet and an outlet, and provides for substantially unobstructed airflow between the ejection head and the outlet when air traverses the airflow path from inlet to outlet. In one embodiment, the ejection head is disposed in the airflow path downstream of the inlet and upstream from the outlet.
- Another embodiment of the invention relates to a method for delivering an aerosolized compound to a patient using a device according to the invention. Such a method comprises inhaling air through such a device while the particle-generating system of the device is actuated. Use of the term “while” encompasses during, immediately thereafter, immediately before, or any such moment that is temporally closely related.
- Another embodiment of the invention relates to a method for generating an air stream containing a compound. This method comprises drawing air through a device of the invention from inlet to outlet while actuating the particle-generating system of the device.
- Further features and advantages of the invention as well as the structure and operation of various embodiments of the invention are described in detail herein with reference to the accompanying drawings.
- The present invention will be described with particular embodiments thereof, and references will be made to the drawings in which:
- FIG. 1 illustrates one embodiment of the device according to the invention; and
- FIG. 2 illustrates a system to generate particles of the desired size according to an embodiment of the invention.
- These drawings are included for illustrative purposes and are in no way intended to limit the scope of use or design of the invention.
- The reservoir and particle-generating system of a device according to the invention may be disposed within, partially within, or outside of the housing of the device. The reservoir, if included, within the housing, may be aerodynamically shaped. In another embodiment, the reservoir is detachable and/or replaceable. In another embodiment, the reservoir and particle-generating system are integrated into a single detachable and/or replaceable unit.
- The system for generating particles can be any system that generates particles of the desired size or size range. In one embodiment, this system is a digitally controlled electronic droplet ejection device. Other embodiments of digitally controlled electronic droplet ejection devices useful in the practice of the invention include those that use heat or a piezoelectric component to generate particles that are ejected from the ejection head.
- The size of the particles is a size that allows the particles to transit to and be deposited in the alveoli. This size may be where at least about 90% of the particles range in size from about 1 μm to about 5 μm such as where the particles have a mass median aerodynamic diameter of about 3 μm. For example, at least about 60% of the particles may have a mass median aerodynamic diameter of about 3 μtm.
- The housing may be of any size, shape and matter that allows for substantially unobstructed airflow. The airflow may be substantially laminar prior to exiting the housing outlet. The housing's inner surface proximal to the ejection head and extending to the outlet may be contoured to minimize turbulence. This substantially unobstructed airflow may comprise a substantially homogeneous mixture of the ejected compound and air in the airflow prior to exiting the housing outlet.
- The term “reservoir” shall be interpreted to mean any container which is suitable to hold and store a compound. The reservoir may be of any shape, size, or material and may be aerodynamically designed so as to facilitate airflow and decrease obstructions in the airflow path. The relative size and optimal shape of the reservoir with respect to other components is variable. For example, altering the size and/or shape of the reservoir may have an impact on the aerodynamics of the system. The reservoir may have an outer layer of material which may be aerodynamically designed, and an inner collapsible bag which is suitable to hold and store a compound. The reservoir is filled with a compound to be administered and may be sealed or have a vent hole through the outer material to allow air displacement for the inner collapsible bag. The reservoir is fluidly connected to the system and may be either permanently connected or may be detachably connected so as to refill the reservoir with a compound.
- The term “system” or “particle-generating system” shall be interpreted to mean any device that can act as an ejection means to eject particles into the airflow. By way of nonexclusive example, the system may compromise a piezoelectric device, such as the kinds (thermal and piezo) used in ink jet printing.
- The term “particles” shall be interpreted to mean small droplets of the compound which are formed upon ejection from the ejection head of the element.
- The term “desired size” shall be interpreted to mean a size which is sufficiently small such that when the particles are formed, they remain suspended in the air for a sufficient amount of time such that they may be inhaled and are sufficiently small such that the particles may be deposited in alveoli upon reaching the lungs. The particles may range in size from about 1 μm to about 5 μm in diameter, such as a mass median aerodynamic diameter of about 3 μm.
- A compound stored in the reservoir of the system can be in any form, and is preferably a liquid formulation. The compound may be any pharmaceutical compound, for example, a protein, a small molecule, or a gene delivery vehicle. Preferred protein embodiments include EPO, G-CSF, GM-CSF, insulin, hGH, factor VIII, FSH, LH, VEGF, an interferon, an interleukin, an antibody or antibody fragment (alone or conjugated to another compound, for example, a cytotoxic agent). Small molecule embodiments include nicotine, methotrexate, albuterol, methadone, or cromylin. Still other embodiments of pharmaceutical compounds include a gene delivery vehicle such as a virus, a liposome, a nucleic acid, a nucleic acid complex, or suspensions thereof.
- The term “compound” shall be interpreted to mean any fluid or liquid formulation such as any pharmaceutical compound.
- The term “small molecule” shall be interpreted to mean any molecule having fewer than one hundred (100) non hydrogen atoms, and having a molecular weight of less than about 1 kDalton.
- The term “fluidly connected” shall be interpreted to mean a connection whereby a fluid may be transferred from the reservoir to the system. This fluid connection may be accomplished in any known way. Non-exclusive examples of such a connection are gravity, a pump, a channel, or capillary feed.
- The term “entry port” shall be interpreted to mean the area or point at which the compound enters the system.
- The term “element to generate particles” shall be interpreted to mean any delivery engine which can generate particles of the desired size.
- The term “ejection head” shall be interpreted to mean the area or point on the system where the particles of the compound are ejected into the air stream.
- The term “housing” shall be interpreted to mean any casing or encased area in which air may flow.
- The term “inlet” shall be interpreted to mean the area or point at which air enters the housing.
- The term “outlet” shall be interpreted to mean the area or point at which air exits the housing.
- The term “airflow path” shall be interpreted to mean the path that the air follows from the inlet to the outlet of the housing.
- The term “disposed” shall be interpreted to mean that the ejection head is connected in any way to the housing such that the ejection head is downstream of the inlet and upstream of the outlet. This connection may be aerodynamically designed such as to decrease airflow obstructions and decrease turbulence in the airflow path.
- The term “substantially unobstructed airflow” shall be interpreted to mean where the airflow path is substantially free of obstructions such as to decrease turbulence. By way of non-exclusive example, this may be accomplished by way of an aerodynamic airflow path.
- The term “pharmaceutical compound” shall be interpreted to mean any molecule or combination of molecules which are capable of performing a pharmaceutical function, e.g., a drug or prodrug which is effective in helping to prevent or treat a disease or condition. “Effective in helping to prevent or treat a disease or condition” indicates that administration in a clinically appropriate manner results in a beneficial effect for at least a statistically significant fraction of patients, such as a improvement of symptoms, a cure, a reduction in disease load, reduction in tumor mass or cell numbers, extension of life, improvement in quality of life, or other effect generally recognized as positive by medical doctors familiar with treating the particular type of disease or condition. The term “pharmaceutical compound” includes but is not limited to any protein, small molecule or gene delivery system.
- Prodrugs include chemical derivatives of a biologically-active parent compound which, upon administration, will eventually liberate the active parent compound in vivo. Use of prodrugs allows the artisan to modify the onset and/or duration of action in vivo. In addition, the use of prodrugs can modify the transportation into, the distribution or solubility of a drug in the body. Furthermore, prodrugs may reduce the toxicity and/or otherwise overcome difficulties encountered when administering a parent pharmaceutical compound.
- Pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- Pharmaceutically acceptable compositions for use in accordance with the present invention thus may be formulated in conventional ways using one or more physiologically acceptable carriers comprising excipients which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Examples include but are not limited to surface tension-controlling agents, humectants, and viscosity-controlling agents; proper formulation may be dependent upon the specific pharmaceutical compound.
- The term “gene delivery vehicle” shall be interpreted to mean any method of delivering an intact gene into an organism such as adenoviral particles or other viruses modified for gene delivery, naked DNA, degradable matrices, and/or such gene delivery systems as mentioned in Dan Luo and W. Mark Saltzman, Synthetic DNA Delivery Systems, Nature Biotechnology, January 2000, at 33-37, which is incorporated herein by reference in its entirety.
- The term “electronic ejection device” shall be interpreted to mean any device which uses electronics to produce and eject particles of the desired size. The electronic ejection device includes, but is not limited to, a thermal device or a piezoelectric device such as those described in U.S. Pat. No. 5,894,841, which is incorporated herein by reference in its entirety.
- The term “uses heat to generate particles” shall be interpreted to mean a thermal device which produces particles of the desired size using heat, such as described in U.S. Pat. No. 5,894,841. A typical thermal device comprises a liquid containing chamber provided with a configured array of nozzles and thin film resistors. A resistor is typically located directly behind each nozzle, for a given nozzle configuration. Each nozzle supplies a droplet or droplets (sometimes satellite droplets are created) of liquid from the chamber if and when a short electrical pulse energizes the corresponding resistor. The resistors thus function as an electronic ejection device. Within a few microseconds liquid in contact with the resistor is vaporized and forms a bubble. The vapor bubble grows rapidly and imparts momentum to liquid adjacent to a bubble. Some of this liquid is ejected as a droplet from an adjacent nozzle. The ejected volume of liquid is then automatically replaced in the chamber from the reservoir by a fluid connection.
- The term “piezoelectric component” shall be interpreted to mean a device generating particles of the desired size by a pressure wave in the fluid produced by applying a voltage pulse to a piezoelectric ceramic which acts as an electronic ejection device. The fluid is ejected through a fine aperture. By way of non-exclusive example, a piezoelectric device is commonly used in inkjet printing.
- The term “alveoli” shall be interpreted to mean components in the pulmonary region of the lung where gas exchange occurs between the air and the lungs and the circulatory system.
- The term “substantially laminar” shall be interpreted to mean a substantially streamline steady flow at a substantially constant velocity. Air and entrained droplet flow is said to be laminar if the substance moves smoothly in layers, one layer (lamina) sliding relative to another. Viscosity and turbulence effects come into play if layers of the flowing substance change their shape as they move, as caused, for example, by airflow path surface irregularities, discontinuities, or the like.
- The term “substantially homogeneous mixture” shall be interpreted to mean a mixture approaching uniform composition throughout.
- The term “contoured to minimize turbulence” shall be interpreted to mean that the housing is designed such that turbulence is minimized and that airflow is approaching substantially constant or smooth laminar flow. By way of non-exclusive example, the inner walls of the housing may be sloped and/or smooth, or may be aerodynamically designed.
- The term “aerosolized compound” shall be interpreted to mean a volume of air of which has suspended droplets comprising the compound within it. For example, the volume could be greater than 2 ml and less than 5 liters.
- The term “substantially non-turbulent airflow” shall be interpreted to mean that the housing is designed so as to reduce and/or minimize turbulence.
- One embodiment of the device is presented in FIGS.1-2. The device in FIG. 1 comprises a
reservoir 1 for storing the compound to be delivered to the patient, asystem 2 to generate particles of a desired size and ahousing 7. The system FIG. 2 comprises anentry port 4 and anelement 5 to general particles of the desired size for ejection from anejection head 6 of the element. The housing comprises aninlet 8 and anoutlet 9. - The
reservoir 1 in this embodiment is disposed within and extends along the length of thehousing 7 and is fluidly connected to thesystem 2 at theentry port 4 and is connected to the housing at theinlet 8 by connection to apower source 10 such as a battery. Thereservoir 1 pictured is a collapsible bladder, however, other forms of a reservoir may be used. For example, the reservoir could be a cylinder fitted with a piston. Thereservoir 1, in one embodiment, is sealed. Thereservoir 1 may also be disposable and/or replaceable. - In one embodiment,
system 2 is disposed entirely or partially within and extends along the length of thehousing 7 and is disposed in the airflow path downstream of theinlet 8 and upstream from theoutlet 9. Thesystem 2 may also be connected to the housing by suspension-like attachments 11 so as to keep the airflow substantially unobstructed. Theejection head 6 of thesystem 2 is disposed in the airflow path upstream of the outlet so as to provide for a mixture area in which the compound, after ejection from the ejection head, mixes with the air flowing from theinlet 8 to theoutlet 9 for delivery to the patient. In this embodiment, theelement 5 to generate particles is of the kind used in a thermal ink jet printer. However, any device that will generate particles of the desired size may be used, such as those described in U.S. Pat. No. 5, 894,841. The compound flows from thereservoir 1 into theelement 5 through theentry port 4 and particles of the desired size are ejected from theejection head 6 into the airflow path “A” which then delivers the compound to the patient. Moreover,element 5 may comprise a silicon wafer, and may be as thick or thin as needed. - For the pulmonary administration of pharmaceuticals, a small particle size is preferred. For example, particles ranging in size from about 1 μm to about 5 μm diameter are acceptable for the pulmonary delivery. Particles with a mass median aerodynamic diameter of about 3 μm are preferable. If necessary, the particle size can be reduced by an optional heating element which can be employed to vaporize the liquid. Particle size can further be reduced by directing the particles ejected from the
ejection head 6 at each another or at a suitable target to further fragment the particles. -
Housing 7 may provide for a substantially unobstructed airflow path so as to minimize turbulence so that the compound stored in thereservoir 1 may be efficiently delivered to the patient. Obstructions in the airflow path result in turbulence which results in some of the compound not reaching the patient. When there is turbulence, particles of the compound deposit on the side of the housing. Therefore, the physical shape and material of the components of the device may be altered so as to decrease turbulence. For example, the reservoir, system and housing may be aerodynamically designed. The reservoir, system and housing may be constructed of materials that decrease turbulence. Suspension-like attachments 11 may be employed to secure the system to the housing to minimize obstructions and turbulence. Other forms of attachment may be used that minimize obstructions and turbulence. - The contents of the articles, patents, and patent applications, and all other documents and electronically available information mentioned or cited herein, are hereby incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Applicants reserve the right to physically incorporate into this application and all materials and information from any such articles, patents, patent applications, or other documents. The inventions illustratively described herein can suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising,” “including”, “containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the future shown and described or portion thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed can be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of the inventions disclosed herein. The inventions have been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of these inventions. This includes the generic description of each invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised materials specifically resided herein. Other embodiments are within the following claims. In addition, where features or aspects of an invention are described in terms of the Markush group, those schooled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
- From the description of the invention herein, it is manifest that various equivalents can be used to implement the concepts of the present invention without departing from its scope. Moreover, while the invention has been described with specific reference to certain embodiments, a person of ordinary skills in the art would recognize that changes can be made in form and detail without departing from the spirit and the scope of the invention. The described embodiments are to be considered in all respects as illustrative and not restrictive. It should also be understood that the invention is not limited to the particular embodiments described herein, but is capable of many equivalents, rearrangements, modifications, and substitutions without departing from the scope of the invention.
Claims (24)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/080,504 US20030072717A1 (en) | 2001-02-23 | 2002-02-22 | Inhalation device having an optimized air flow path |
US12/404,110 US8201554B2 (en) | 2001-02-23 | 2009-03-13 | Inhalation device having an optimized air flow path |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27119301P | 2001-02-23 | 2001-02-23 | |
US10/080,504 US20030072717A1 (en) | 2001-02-23 | 2002-02-22 | Inhalation device having an optimized air flow path |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/404,110 Continuation US8201554B2 (en) | 2001-02-23 | 2009-03-13 | Inhalation device having an optimized air flow path |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030072717A1 true US20030072717A1 (en) | 2003-04-17 |
Family
ID=26763607
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/080,504 Abandoned US20030072717A1 (en) | 2001-02-23 | 2002-02-22 | Inhalation device having an optimized air flow path |
US12/404,110 Expired - Fee Related US8201554B2 (en) | 2001-02-23 | 2009-03-13 | Inhalation device having an optimized air flow path |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/404,110 Expired - Fee Related US8201554B2 (en) | 2001-02-23 | 2009-03-13 | Inhalation device having an optimized air flow path |
Country Status (1)
Country | Link |
---|---|
US (2) | US20030072717A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050172956A1 (en) * | 2004-02-11 | 2005-08-11 | Childers Winthrop D. | Medicament dispenser |
US20060289002A1 (en) * | 2005-06-24 | 2006-12-28 | Pari Gmbh Spezialisten Fur Effektive Inhalation | Inhalation therapy device |
EP1818070A2 (en) * | 2006-02-10 | 2007-08-15 | Pari GmbH | Inhalation therapy device for use with premature babies and infants |
WO2007107160A1 (en) | 2006-03-21 | 2007-09-27 | Bang & Olufsen Medicom A/S | Inhaler flow channel |
US7467630B2 (en) | 2004-02-11 | 2008-12-23 | Hewlett-Packard Development Company, L.P. | Medicament dispenser |
US20090173341A1 (en) * | 2001-02-23 | 2009-07-09 | Injet Digital Aerosols Limited | Inhalation device having an optimized air flow path |
WO2009128556A1 (en) * | 2008-04-16 | 2009-10-22 | Canon Kabushiki Kaisha | Ejection head cartridge and inhalation apparatus the same is attachable thereto |
WO2009135871A1 (en) * | 2008-05-09 | 2009-11-12 | Pari Pharma Gmbh | Atomizer for ventilation machines and ventilation machine comprising said atomizer |
US20110297146A1 (en) * | 2009-04-14 | 2011-12-08 | Canon Kabushiki Kaisha | Liquid ejection head to be used for inhaler and inhaler |
US20110303222A1 (en) * | 2009-04-14 | 2011-12-15 | Canon Kabushiki Kaisha | Liquid ejection head and inhaler |
US8495998B2 (en) | 2009-06-17 | 2013-07-30 | British American Tobacco (Investments) Limited | Inhaler |
US20150090253A1 (en) * | 2013-09-30 | 2015-04-02 | Darrin B. Farrow | Vaporization device and method of preparation and use |
AU2013201359B2 (en) * | 2008-05-09 | 2015-09-17 | Pari Pharma Gmbh | Atomizer for Ventilation Machines and Ventilation Machine Comprising said Atomizer |
WO2017011868A1 (en) * | 2015-07-20 | 2017-01-26 | Medical Developments International Limited | Inhaler device for inhalable liquids |
AU2015264908B2 (en) * | 2008-05-09 | 2017-06-29 | Pari Pharma Gmbh | Nebuliser for Ventilation Machines and a Ventilation Machine Comprising such a Nebuliser |
WO2017192767A1 (en) | 2016-05-03 | 2017-11-09 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
US20170360099A1 (en) * | 2016-06-20 | 2017-12-21 | Fabien DUC | Vaporiser assembly for an aerosol-generating system |
WO2017220273A1 (en) * | 2016-06-20 | 2017-12-28 | Philip Morris Products S.A. | Vaporiser assembly for an aerosol-generating system |
CN108472457A (en) * | 2015-12-28 | 2018-08-31 | 皇家飞利浦有限公司 | Air flowing in atomizer head |
WO2019115771A1 (en) | 2017-12-15 | 2019-06-20 | Pari Pharma Gmbh | Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method |
CN111526914A (en) * | 2017-10-04 | 2020-08-11 | 精呼吸股份有限公司 | Electronic respiration actuated linear liquid drop conveying device and using method thereof |
JP2021510108A (en) * | 2018-01-08 | 2021-04-15 | ニューマ・リスパイラトリー・インコーポレイテッド | Treatment of lung cancer using a droplet delivery device that is electrically actuated by breathing |
US11458267B2 (en) | 2017-10-17 | 2022-10-04 | Pneuma Respiratory, Inc. | Nasal drug delivery apparatus and methods of use |
US11529476B2 (en) | 2017-05-19 | 2022-12-20 | Pneuma Respiratory, Inc. | Dry powder delivery device and methods of use |
US11771852B2 (en) | 2017-11-08 | 2023-10-03 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use |
US11793945B2 (en) | 2021-06-22 | 2023-10-24 | Pneuma Respiratory, Inc. | Droplet delivery device with push ejection |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8528544B2 (en) * | 2007-05-30 | 2013-09-10 | Canon Kabushiki Kaisha | Inhaler |
CA2709071C (en) | 2007-12-14 | 2016-11-15 | Labogroup S.A.S. | Delivering aerosolizable food products |
US8499764B2 (en) | 2010-05-26 | 2013-08-06 | The Invention Science Fund I, Llc | Portable apparatus for establishing an isolation field |
US10034988B2 (en) | 2012-11-28 | 2018-07-31 | Fontem Holdings I B.V. | Methods and devices for compound delivery |
WO2015042412A1 (en) | 2013-09-20 | 2015-03-26 | E-Nicotine Technology. Inc. | Devices and methods for modifying delivery devices |
US10292424B2 (en) * | 2013-10-31 | 2019-05-21 | Rai Strategic Holdings, Inc. | Aerosol delivery device including a pressure-based aerosol delivery mechanism |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US455614A (en) * | 1891-07-07 | Sivioking device | ||
US1105934A (en) * | 1913-07-12 | 1914-08-04 | Ernest J Stevens | Inhaler. |
US1272579A (en) * | 1918-01-26 | 1918-07-16 | George W Todd | Dispensing-receptacle for liquid anesthetics. |
US2084299A (en) * | 1934-12-15 | 1937-06-15 | Arthur G Borden | Medicament holder for nasal inhalers |
US2086588A (en) * | 1935-11-18 | 1937-07-13 | Joseph J Tobin | Vaporizing applicator |
US2449853A (en) * | 1947-08-05 | 1948-09-21 | Karp George | Inhaler |
US3812854A (en) * | 1972-10-20 | 1974-05-28 | A Michaels | Ultrasonic nebulizer |
US3820540A (en) * | 1971-12-07 | 1974-06-28 | H Hirtz | Electrical appliance |
US3970250A (en) * | 1974-09-25 | 1976-07-20 | Siemens Aktiengesellschaft | Ultrasonic liquid atomizer |
US4653494A (en) * | 1985-12-20 | 1987-03-31 | Ruderian Max J | Nasal inhalation system |
US4735217A (en) * | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US5060671A (en) * | 1989-12-01 | 1991-10-29 | Philip Morris Incorporated | Flavor generating article |
US5144962A (en) * | 1989-12-01 | 1992-09-08 | Philip Morris Incorporated | Flavor-delivery article |
US5170782A (en) * | 1991-09-12 | 1992-12-15 | Devilbiss Health Care, Inc. | Medicament nebulizer with improved aerosol chamber |
US5261601A (en) * | 1989-12-12 | 1993-11-16 | Bespak Plc | Liquid dispensing apparatus having a vibrating perforate membrane |
US5388574A (en) * | 1993-07-29 | 1995-02-14 | Ingebrethsen; Bradley J. | Aerosol delivery article |
US5429302A (en) * | 1993-05-19 | 1995-07-04 | Fisons Corporation | Nebulizing element and device |
US5443059A (en) * | 1993-01-15 | 1995-08-22 | Dragerwerk Ag | Ultrasonic atomizer with a metering unit |
US5485828A (en) * | 1992-04-29 | 1996-01-23 | Hauser; Jean-Luc | Portable device for micropulverization generated by ultrasound waves |
US5551416A (en) * | 1991-11-12 | 1996-09-03 | Medix Limited | Nebuliser and nebuliser control system |
US5666977A (en) * | 1993-06-10 | 1997-09-16 | Philip Morris Incorporated | Electrical smoking article using liquid tobacco flavor medium delivery system |
US5694920A (en) * | 1996-01-25 | 1997-12-09 | Abrams; Andrew L. | Inhalation device |
US5724957A (en) * | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
US5894841A (en) * | 1993-06-29 | 1999-04-20 | Ponwell Enterprises Limited | Dispenser |
US6435175B1 (en) * | 2000-08-29 | 2002-08-20 | Sensormedics Corporation | Pulmonary drug delivery device |
US6571793B1 (en) * | 2000-09-21 | 2003-06-03 | Microdrug Ag | Optimization of an electrostatically dosed dry powder inhaler |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5953565A (en) | 1982-09-20 | 1984-03-28 | Dainippon Toryo Co Ltd | Jet ink composition |
US4685968A (en) * | 1985-12-05 | 1987-08-11 | Hewlett-Packard Company | Process for preparing ink compositions for ink-jets printers |
US4694302A (en) * | 1986-06-06 | 1987-09-15 | Hewlett-Packard Company | Reactive ink-jet printing |
JP2656944B2 (en) | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | Aerosolization of protein therapeutics |
JP2931846B2 (en) * | 1988-11-07 | 1999-08-09 | 松下電器産業株式会社 | Panel switch and manufacturing method thereof |
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5062892A (en) * | 1989-10-27 | 1991-11-05 | Hewlett-Packard Company | Ink additives for improved ink-jet performance |
US5047084A (en) * | 1990-01-23 | 1991-09-10 | Hewlett-Packard Company | Microemulsion ink jet ink composition |
ES2065434T3 (en) * | 1990-06-21 | 1995-02-16 | Edith Dr Huland | USE OF AEROSOLS CONTAINING CYTOKINES AND AEROSOLS CONTAINING CYTOKINES PROPERLY SAID. |
DE4026072A1 (en) * | 1990-08-17 | 1992-02-20 | Sanol Arznei Schwarz Gmbh | NITROGLYCER-CONTAINING, HYDROPHILIC, WAESSRING PUMPSPRAY |
GB9027363D0 (en) | 1990-12-18 | 1991-02-06 | Gillette Co | Shampoo compositions |
JP3532204B2 (en) * | 1991-03-05 | 2004-05-31 | アラダイム コーポレーション | Method and apparatus for correcting drift offset of a flow sensor pressure sensor |
US5404871A (en) * | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5450336A (en) * | 1991-03-05 | 1995-09-12 | Aradigm Corporation | Method for correcting the drift offset of a transducer |
US5505214A (en) * | 1991-03-11 | 1996-04-09 | Philip Morris Incorporated | Electrical smoking article and method for making same |
US5120528A (en) | 1991-06-12 | 1992-06-09 | Block Drug Company, Inc. | Taste preserving, mild oral hygiene compositions |
US5413732A (en) * | 1991-08-19 | 1995-05-09 | Abaxis, Inc. | Reagent compositions for analytical testing |
US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
US5639441A (en) * | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
JP3178945B2 (en) * | 1992-08-25 | 2001-06-25 | 日本碍子株式会社 | Inkjet print head |
GB2272389B (en) * | 1992-11-04 | 1996-07-24 | Bespak Plc | Dispensing apparatus |
US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
IS1796B (en) | 1993-06-24 | 2001-12-31 | Ab Astra | Inhaled polypeptide formulation composition which also contains an enhancer compound |
EP0710102A1 (en) | 1993-07-19 | 1996-05-08 | Amgen Inc. | Stabilization of aerosolized proteins |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US6228383B1 (en) * | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
WO1996028205A1 (en) * | 1995-03-14 | 1996-09-19 | Siemens Aktiengesellschaft | Ultrasonic atomizer device with removable precision dosing unit |
US5808637A (en) * | 1995-05-26 | 1998-09-15 | Hewlett-Packard Company | Method and apparatus for ink drop trajectory control |
US5715866A (en) * | 1995-12-29 | 1998-02-10 | Granger; Melforde A. | Portable fluid dispensing apparatus |
US6026809A (en) * | 1996-01-25 | 2000-02-22 | Microdose Technologies, Inc. | Inhalation device |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
USRE37053E1 (en) * | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
US5934289A (en) * | 1996-10-22 | 1999-08-10 | Philip Morris Incorporated | Electronic smoking system |
ATE298740T1 (en) * | 1997-04-04 | 2005-07-15 | Mitsubishi Pharma Corp | 2-AMINOPROPANE-1,3-DIOL COMPOUNDS, THEIR MEDICAL APPLICATION AND INTERMEDIATE PRODUCTS FOR THEIR SYNTHESIS |
KR100593238B1 (en) * | 1997-06-25 | 2006-06-26 | 데이진 가부시키가이샤 | Vitamin D3 derivatives and remedies for inflammatory respiratory diseases prepared from the same |
PL195212B1 (en) | 1997-09-29 | 2007-08-31 | Nektar Therapeutics | Perforated microparticles and method of using them |
EP1029536B1 (en) * | 1997-10-01 | 2007-11-28 | Novadel Pharma Inc. | Buccal non-polar spray |
CA2228182C (en) * | 1998-01-26 | 2007-03-20 | George Volgyesi | Breath-powered mist inhaler |
US6451285B2 (en) * | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US20030072717A1 (en) * | 2001-02-23 | 2003-04-17 | Vapotronics, Inc. | Inhalation device having an optimized air flow path |
CN1236831C (en) * | 2001-05-21 | 2006-01-18 | 茵捷特数码浮质有限公司 | Compositions for protein delivery via the pulmonary route |
WO2004022128A2 (en) * | 2002-09-06 | 2004-03-18 | Chrysalis Technologies Incorporated | Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols |
-
2002
- 2002-02-22 US US10/080,504 patent/US20030072717A1/en not_active Abandoned
-
2009
- 2009-03-13 US US12/404,110 patent/US8201554B2/en not_active Expired - Fee Related
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US455614A (en) * | 1891-07-07 | Sivioking device | ||
US1105934A (en) * | 1913-07-12 | 1914-08-04 | Ernest J Stevens | Inhaler. |
US1272579A (en) * | 1918-01-26 | 1918-07-16 | George W Todd | Dispensing-receptacle for liquid anesthetics. |
US2084299A (en) * | 1934-12-15 | 1937-06-15 | Arthur G Borden | Medicament holder for nasal inhalers |
US2086588A (en) * | 1935-11-18 | 1937-07-13 | Joseph J Tobin | Vaporizing applicator |
US2449853A (en) * | 1947-08-05 | 1948-09-21 | Karp George | Inhaler |
US3820540A (en) * | 1971-12-07 | 1974-06-28 | H Hirtz | Electrical appliance |
US3812854A (en) * | 1972-10-20 | 1974-05-28 | A Michaels | Ultrasonic nebulizer |
US3970250A (en) * | 1974-09-25 | 1976-07-20 | Siemens Aktiengesellschaft | Ultrasonic liquid atomizer |
US4653494A (en) * | 1985-12-20 | 1987-03-31 | Ruderian Max J | Nasal inhalation system |
US4735217A (en) * | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US5060671A (en) * | 1989-12-01 | 1991-10-29 | Philip Morris Incorporated | Flavor generating article |
US5144962A (en) * | 1989-12-01 | 1992-09-08 | Philip Morris Incorporated | Flavor-delivery article |
US5261601A (en) * | 1989-12-12 | 1993-11-16 | Bespak Plc | Liquid dispensing apparatus having a vibrating perforate membrane |
US5170782A (en) * | 1991-09-12 | 1992-12-15 | Devilbiss Health Care, Inc. | Medicament nebulizer with improved aerosol chamber |
US5551416A (en) * | 1991-11-12 | 1996-09-03 | Medix Limited | Nebuliser and nebuliser control system |
US5485828A (en) * | 1992-04-29 | 1996-01-23 | Hauser; Jean-Luc | Portable device for micropulverization generated by ultrasound waves |
US5443059A (en) * | 1993-01-15 | 1995-08-22 | Dragerwerk Ag | Ultrasonic atomizer with a metering unit |
US5724957A (en) * | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
US5429302A (en) * | 1993-05-19 | 1995-07-04 | Fisons Corporation | Nebulizing element and device |
US5666977A (en) * | 1993-06-10 | 1997-09-16 | Philip Morris Incorporated | Electrical smoking article using liquid tobacco flavor medium delivery system |
US5894841A (en) * | 1993-06-29 | 1999-04-20 | Ponwell Enterprises Limited | Dispenser |
US5388574A (en) * | 1993-07-29 | 1995-02-14 | Ingebrethsen; Bradley J. | Aerosol delivery article |
US5694920A (en) * | 1996-01-25 | 1997-12-09 | Abrams; Andrew L. | Inhalation device |
US6435175B1 (en) * | 2000-08-29 | 2002-08-20 | Sensormedics Corporation | Pulmonary drug delivery device |
US6571793B1 (en) * | 2000-09-21 | 2003-06-03 | Microdrug Ag | Optimization of an electrostatically dosed dry powder inhaler |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090173341A1 (en) * | 2001-02-23 | 2009-07-09 | Injet Digital Aerosols Limited | Inhalation device having an optimized air flow path |
US8201554B2 (en) | 2001-02-23 | 2012-06-19 | Injet Digital Aerosols Limited | Inhalation device having an optimized air flow path |
US20050172956A1 (en) * | 2004-02-11 | 2005-08-11 | Childers Winthrop D. | Medicament dispenser |
US7467630B2 (en) | 2004-02-11 | 2008-12-23 | Hewlett-Packard Development Company, L.P. | Medicament dispenser |
US7481213B2 (en) | 2004-02-11 | 2009-01-27 | Hewlett-Packard Development Company, L.P. | Medicament dispenser |
US20060289002A1 (en) * | 2005-06-24 | 2006-12-28 | Pari Gmbh Spezialisten Fur Effektive Inhalation | Inhalation therapy device |
US7779838B2 (en) | 2005-06-24 | 2010-08-24 | Pari Pharma Gmbh | Inhalation therapy device |
EP1818070A2 (en) * | 2006-02-10 | 2007-08-15 | Pari GmbH | Inhalation therapy device for use with premature babies and infants |
EP2567724A3 (en) * | 2006-02-10 | 2013-06-05 | PARI Pharma GmbH | Inhalation therapy device |
EP1818070A3 (en) * | 2006-02-10 | 2012-11-07 | PARI Pharma GmbH | Inhalation therapy device for use with premature babies and infants |
WO2007107160A1 (en) | 2006-03-21 | 2007-09-27 | Bang & Olufsen Medicom A/S | Inhaler flow channel |
WO2009128556A1 (en) * | 2008-04-16 | 2009-10-22 | Canon Kabushiki Kaisha | Ejection head cartridge and inhalation apparatus the same is attachable thereto |
JP2009254557A (en) * | 2008-04-16 | 2009-11-05 | Canon Inc | Ejection head cartridge and inhalation apparatus the same is attachable thereto |
US8757145B2 (en) * | 2008-04-16 | 2014-06-24 | Canon Kabushiki Kaisha | Ejection head cartridge and inhalation apparatus the same is attachable thereto |
US20100319692A1 (en) * | 2008-04-16 | 2010-12-23 | Canon Kabushiki Kaisha | Ejection head cartridge and inhalation apparatus the same is attachable thereto |
EP2548598A1 (en) | 2008-05-09 | 2013-01-23 | PARI Pharma GmbH | Atomiser for respiration machines and respiration machine with such an atomiser |
EP2848275A3 (en) * | 2008-05-09 | 2015-07-08 | PARI Pharma GmbH | Atomiser for respiration machines and respiration machine with such an atomiser |
WO2009135871A1 (en) * | 2008-05-09 | 2009-11-12 | Pari Pharma Gmbh | Atomizer for ventilation machines and ventilation machine comprising said atomizer |
AU2015264908B2 (en) * | 2008-05-09 | 2017-06-29 | Pari Pharma Gmbh | Nebuliser for Ventilation Machines and a Ventilation Machine Comprising such a Nebuliser |
US20110146670A1 (en) * | 2008-05-09 | 2011-06-23 | Pari Pharma Gmbh | Nebuliser for ventilation machines and a ventilation machine comprising such a nebuliser |
US9687627B2 (en) * | 2008-05-09 | 2017-06-27 | Pari Pharma Gmbh | Nebuliser for ventilation machines and a ventilation machine comprising such a nebuliser |
AU2009245802B2 (en) * | 2008-05-09 | 2013-11-07 | Pari Pharma Gmbh | Atomizer for ventilation machines and ventilation machine comprising said atomizer |
US8720435B2 (en) | 2008-05-09 | 2014-05-13 | Pari Pharma Gmbh | Nebuliser for ventilation machines and a ventilation machine comprising such a nebuliser |
DE102008022987A1 (en) | 2008-05-09 | 2009-11-12 | Pari Pharma Gmbh | Nebulizer for respirators and ventilator with such a nebulizer |
EP2848275A2 (en) | 2008-05-09 | 2015-03-18 | PARI Pharma GmbH | Atomiser for respiration machines and respiration machine with such an atomiser |
US20150306334A1 (en) * | 2008-05-09 | 2015-10-29 | Pari Pharma Gmbh | Nebuliser for ventilation machines and a ventilation machine comprising such a nebuliser |
AU2013201359B2 (en) * | 2008-05-09 | 2015-09-17 | Pari Pharma Gmbh | Atomizer for Ventilation Machines and Ventilation Machine Comprising said Atomizer |
US9095676B2 (en) | 2008-05-09 | 2015-08-04 | Pari Pharma Gmbh | Nebuliser for ventilation machines and a ventilation machine comprising such a nebuliser |
US20110303222A1 (en) * | 2009-04-14 | 2011-12-15 | Canon Kabushiki Kaisha | Liquid ejection head and inhaler |
US20110297146A1 (en) * | 2009-04-14 | 2011-12-08 | Canon Kabushiki Kaisha | Liquid ejection head to be used for inhaler and inhaler |
US8495998B2 (en) | 2009-06-17 | 2013-07-30 | British American Tobacco (Investments) Limited | Inhaler |
US20150090253A1 (en) * | 2013-09-30 | 2015-04-02 | Darrin B. Farrow | Vaporization device and method of preparation and use |
US9730472B2 (en) * | 2013-09-30 | 2017-08-15 | Darrin B. Farrow | Vaporization device and method of preparation and use |
WO2017011868A1 (en) * | 2015-07-20 | 2017-01-26 | Medical Developments International Limited | Inhaler device for inhalable liquids |
RU2720159C2 (en) * | 2015-07-20 | 2020-04-24 | Медикал Дивелопментс Интернэшнл Лимитед | Inhaler device for inhalation liquids |
CN108472457A (en) * | 2015-12-28 | 2018-08-31 | 皇家飞利浦有限公司 | Air flowing in atomizer head |
EP3397329B1 (en) * | 2015-12-28 | 2023-03-08 | Koninklijke Philips N.V. | Air-flow in a nebulizer head |
AU2016380926B2 (en) * | 2015-12-28 | 2021-12-23 | Koninklijke Philips N.V. | Air-flow in a nebulizer head |
WO2017192767A1 (en) | 2016-05-03 | 2017-11-09 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
US10898666B2 (en) | 2016-05-03 | 2021-01-26 | Pneuma Respiratory, Inc. | Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device |
US9956360B2 (en) * | 2016-05-03 | 2018-05-01 | Pneuma Respiratory, Inc. | Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device |
US9962507B2 (en) * | 2016-05-03 | 2018-05-08 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
JP7407593B2 (en) | 2016-05-03 | 2024-01-04 | ニューマ・リスパイラトリー・インコーポレイテッド | Droplet delivery device for delivering fluid to the pulmonary system and method of use thereof |
CN109475707A (en) * | 2016-05-03 | 2019-03-15 | 精呼吸股份有限公司 | Drop conveying device and its application method for trandfer fluid to pulmonary system |
JP2019515764A (en) * | 2016-05-03 | 2019-06-13 | ニューマ・リスパイラトリー・インコーポレイテッド | Droplet delivery device for supplying fluid to the pulmonary system and method of use thereof |
US20170319797A1 (en) * | 2016-05-03 | 2017-11-09 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
US10449314B2 (en) | 2016-05-03 | 2019-10-22 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
EP3452152A4 (en) * | 2016-05-03 | 2020-01-01 | Pneuma Respiratory, Inc. | Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device |
US10525220B2 (en) | 2016-05-03 | 2020-01-07 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
EP3452150A4 (en) * | 2016-05-03 | 2020-01-08 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
WO2017192771A1 (en) | 2016-05-03 | 2017-11-09 | Pneuma Respiratory, Inc. | Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device |
US11285283B2 (en) | 2016-05-03 | 2022-03-29 | Pneuma Respiratory, Inc. | Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device |
US11285274B2 (en) | 2016-05-03 | 2022-03-29 | Pneuma Respiratory, Inc. | Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device |
US11285284B2 (en) | 2016-05-03 | 2022-03-29 | Pneuma Respiratory, Inc. | Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency |
AU2019210668B2 (en) * | 2016-05-03 | 2021-03-18 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
US11285285B2 (en) | 2016-05-03 | 2022-03-29 | Pneuma Respiratory, Inc. | Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment |
US20170319796A1 (en) * | 2016-05-03 | 2017-11-09 | Pneuma Respiratory, Inc. | Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device |
US11778696B2 (en) | 2016-06-20 | 2023-10-03 | Altria Client Services Llc | Vaporiser assembly for an aerosol-generating system |
WO2017220273A1 (en) * | 2016-06-20 | 2017-12-28 | Philip Morris Products S.A. | Vaporiser assembly for an aerosol-generating system |
US10881140B2 (en) * | 2016-06-20 | 2021-01-05 | Altria Client Services Llc | Vaporiser assembly for an aerosol-generating system |
US20170360099A1 (en) * | 2016-06-20 | 2017-12-21 | Fabien DUC | Vaporiser assembly for an aerosol-generating system |
US11529476B2 (en) | 2017-05-19 | 2022-12-20 | Pneuma Respiratory, Inc. | Dry powder delivery device and methods of use |
CN111526914A (en) * | 2017-10-04 | 2020-08-11 | 精呼吸股份有限公司 | Electronic respiration actuated linear liquid drop conveying device and using method thereof |
US11738158B2 (en) | 2017-10-04 | 2023-08-29 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device and methods of use |
EP3691728A4 (en) * | 2017-10-04 | 2021-06-30 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device and methods of use |
US11458267B2 (en) | 2017-10-17 | 2022-10-04 | Pneuma Respiratory, Inc. | Nasal drug delivery apparatus and methods of use |
US11771852B2 (en) | 2017-11-08 | 2023-10-03 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use |
WO2019115771A1 (en) | 2017-12-15 | 2019-06-20 | Pari Pharma Gmbh | Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method |
JP2021510108A (en) * | 2018-01-08 | 2021-04-15 | ニューマ・リスパイラトリー・インコーポレイテッド | Treatment of lung cancer using a droplet delivery device that is electrically actuated by breathing |
US11793945B2 (en) | 2021-06-22 | 2023-10-24 | Pneuma Respiratory, Inc. | Droplet delivery device with push ejection |
Also Published As
Publication number | Publication date |
---|---|
US8201554B2 (en) | 2012-06-19 |
US20090173341A1 (en) | 2009-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8201554B2 (en) | Inhalation device having an optimized air flow path | |
RU2367466C2 (en) | Ejection fluid, ejection technique, fluid drop formation method, ejection fluid cartridge and ejector | |
ES2251834T3 (en) | APPARATUS FOR THE NEBULIZATION OF A LIQUID WITHIN A PORTABLE INHALER. | |
EP1927373B1 (en) | Inhalation nebulizer | |
US7605124B2 (en) | Ejection liquid and ejection method | |
US20090022669A1 (en) | Compositions for protein delivery via the pulmonary route | |
JP4646669B2 (en) | Discharge liquid, discharge method, droplet forming method, cartridge, and discharge device | |
EP2018224B1 (en) | Dissociated discharge ehd sprayer with electric field shield | |
JP4147235B2 (en) | Discharge liquid, discharge method, droplet forming method, liquid discharge cartridge, and discharge apparatus | |
AU2002310054A1 (en) | Compositions for protein delivery via the pulmonary route | |
EP1882487B1 (en) | Inhaler | |
JP4498335B2 (en) | Inhaler | |
Trees et al. | Dissociated discharge EHD sprayer with electric field shield | |
MXPA06006284A (en) | Portable gas operating inhaler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VAPOTRONICS INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REINHOLD, OLAF;TAUB, JEFFREY P.;LACKEY, ROBERT P.;AND OTHERS;REEL/FRAME:013207/0678;SIGNING DATES FROM 20020524 TO 20020724 |
|
AS | Assignment |
Owner name: INJET DIGITAL AEROSOLS LIMITED, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PONWELL ENTERPRISES, LIMITED;REEL/FRAME:014592/0595 Effective date: 20030829 |
|
AS | Assignment |
Owner name: INTERNATIONAL BUSINESS MACHINES CORPORATION, NEW Y Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLANCHARD, ANTON;MILLER, MILTON DEVON II;VENTON, TODD ALAN;REEL/FRAME:015084/0454 Effective date: 20040804 |
|
AS | Assignment |
Owner name: INJET DIGITAL AEROSOLS LIMITED, AUSTRALIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNOR PREVIOUSLY RECORDED ON REEL 014592 FRAME 0595;ASSIGNOR:VAPOTRONICS, INC.;REEL/FRAME:015356/0095 Effective date: 20030829 |
|
AS | Assignment |
Owner name: CANON KABUSHIKI KAISHA, JAPAN Free format text: LICENSE;ASSIGNOR:INJET DIGITAL AEROSOLS LIMITED;REEL/FRAME:017213/0564 Effective date: 20030827 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |